Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of polatuzumab vedotin when given with
combination chemotherapy for the treatment of patients with untreated large B-cell lymphoma
that grows and spreads quickly and has severe symptoms (aggressive). Polatuzumab vedotin is a
monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab
attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them.
Drugs used in combination chemotherapy such as etoposide, cyclophosphamide, and doxorubicin
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal
antibody that may interfere with the ability of cancer cells to grow and spread.
Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used
with other drugs in the treatment of some types of cancer. Giving polatuzumab vedotin in
addition to etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab may help treat
patients with aggressive large B-cell lymphoma.